A Phase I trial (NCT04047706) is presently studying the potential side effects of administering nivolumab, BMS-986,205 (an IDO1 inhibitor), and conventional radiation therapy, either alone or in combination with TMZ, to patients with newly diagnosed GBM [50]. Here, IDO1 is linked to glioblastoma.